New combo attack on stubborn cancers shows promise in early trial

NCT ID NCT03728361

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether combining the immunotherapy drug nivolumab with the chemotherapy drug temozolomide can shrink tumors in people with small-cell lung cancer that has returned or not responded to treatment, or advanced neuroendocrine tumors. About 55 participants will receive both drugs intravenously and by mouth. The main goal is to see how many patients have their tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nivolumab (Opdivo) and temozolomide (Temodar)
What this could lead to
If it works, this combination could offer a new treatment option for patients with hard-to-treat small-cell lung cancer or advanced neuroendocrine tumors.
What could go wrong
This is a phase II trial with only 55 participants, so results are preliminary. The combination may cause significant side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRADE I NEUROENDOCRINE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ohio State University Comprehensive Cancer Center-COHORT 1

    Columbus, Ohio, 43210, United States

  • Ohio State University Comprehensive Cancer Center-COHORT 2

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.